Abbott Laboratories Director Receives Routine Stock Equivalent Units Fee Grant
ABBOTT LABORATORIES
Subscribe to track ABT
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📊 Insider Transaction Report: Abbott Laboratories (ABT)
Insider: Stratton John G Role: Director Type: Acquisition (Stock Equivalent Units) Shares Transacted: 397 Price per Share: $98.83 Total Value: $39,235.51 Post-Transaction Holdings: 14,499 units
Note: Routine credit of director fees under grantor trust deferral plan.
Comprehensive Analysis
Insider Filing Analysis: Abbott Laboratories (NYSE: ABT)
Overview
On October 2, 2026, Abbott Laboratories Director John G. Stratton reported an acquisition of 397 Stock Equivalent Units on September 30, 2026, at a price of $98.83 per share, totaling approximately $39,235.51.
Transaction Details
- Transaction Code:
A(Award / Acquisition) - Security: Stock Equivalent Units (convertible/payable in cash generally at retirement or age 65)
- Shares Acquired: 397
- Price: $98.83
- Post-Transaction Beneficial Ownership: 14,499 units (including units accumulated via dividend reinvestment)
Significance and Context
This transaction represents a routine quarterly director fee deferral credited to a stock equivalent unit account under a grantor trust. Because this reflects predetermined board compensation structure rather than discretionary open-market purchasing, it holds low informational value for market sentiment or near-term share price trajectory.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.